NASDAQ:IFRX InflaRx (IFRX) Stock Forecast, Price & News $4.15 -0.06 (-1.43%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$4.11▼$4.2650-Day Range$1.78▼$6.1052-Week Range$0.78▼$7.25Volume183,196 shsAverage Volume345,001 shsMarket Capitalization$185.51 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media InflaRx MarketRank™ ForecastAnalyst RatingBuy3.20 Rating ScoreUpside/Downside237.3% Upside$14.00 Price TargetShort InterestHealthy1.58% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.26) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector534th out of 985 stocksPharmaceutical Preparations Industry261st out of 483 stocks 3.6 Analyst's Opinion Consensus RatingInflaRx has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, InflaRx has a forecasted upside of 237.3% from its current price of $4.15.Amount of Analyst CoverageInflaRx has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.58% of the outstanding shares of InflaRx have been sold short.Short Interest Ratio / Days to CoverInflaRx has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InflaRx has recently decreased by 26.28%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldInflaRx does not currently pay a dividend.Dividend GrowthInflaRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IFRX. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 4 people have searched for IFRX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added InflaRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -94% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, InflaRx insiders have not sold or bought any company stock.Percentage Held by Insiders16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.04% of the stock of InflaRx is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for InflaRx are expected to grow in the coming year, from ($1.26) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InflaRx is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InflaRx is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInflaRx has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About InflaRx (NASDAQ:IFRX) StockInflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.Read More Receive IFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter. Email Address IFRX Stock News HeadlinesMay 22, 2023 | americanbankingnews.comInflaRx (NASDAQ:IFRX) vs. Viveon Health Acquisition (NYSE:VHAQ) Head to Head ContrastMay 15, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on InflaRx (IFRX)June 6, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 12, 2023 | markets.businessinsider.comRaymond James Remains a Buy on InflaRx (IFRX)May 12, 2023 | msn.comRaymond James Maintains InflaRx N.V. (IFRX) Strong Buy RecommendationMay 12, 2023 | msn.comHC Wainwright & Co. Reiterates InflaRx N.V. (IFRX) Buy RecommendationMay 11, 2023 | finanznachrichten.deInflaRx N.V.: InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business UpdateMay 11, 2023 | finance.yahoo.comInflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business UpdateJune 6, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 11, 2023 | markets.businessinsider.comLifeSci Capital Reaffirms Their Buy Rating on InflaRx (IFRX)May 3, 2023 | finance.yahoo.comInflaRx N.V.'s (NASDAQ:IFRX) Profit OutlookApril 22, 2023 | americanbankingnews.comInflaRx (NASDAQ:IFRX) PT Lowered to $9.00 at HC WainwrightApril 18, 2023 | finance.yahoo.comInflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 millionApril 15, 2023 | finanznachrichten.deInflaRx N.V.: InflaRx Announces Closing of $40 Million Public Offering of Ordinary SharesApril 14, 2023 | finance.yahoo.comInflaRx Announces Closing of $40 Million Public Offering of Ordinary SharesApril 12, 2023 | finanznachrichten.deInflaRx N.V.: InflaRx Announces Public Offering of Ordinary SharesApril 12, 2023 | finanznachrichten.deInflaRx N.V.: InflaRx Announces Pricing of $40 Million Public Offering of Ordinary SharesApril 12, 2023 | finance.yahoo.comInflaRx Announces Pricing of $40 Million Public Offering of Ordinary SharesApril 11, 2023 | finance.yahoo.comInflaRx Announces Public Offering of Ordinary SharesApril 8, 2023 | americanbankingnews.comInflaRx (NASDAQ:IFRX) Price Target Raised to $10.00 at HC WainwrightApril 8, 2023 | americanbankingnews.comInflaRx (NASDAQ:IFRX) Given New $25.00 Price Target at Raymond JamesApril 7, 2023 | americanbankingnews.comInflaRx (NASDAQ:IFRX) Stock Rating Upgraded by GuggenheimApril 7, 2023 | americanbankingnews.comStock Traders Buy High Volume of InflaRx Call Options (NASDAQ:IFRX)April 6, 2023 | americanbankingnews.comInflaRx (NASDAQ:IFRX) Upgraded by Lifesci Capital to "Outperform"April 5, 2023 | finance.yahoo.comInflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 TreatmentApril 5, 2023 | finance.yahoo.comWhy Shares of InflaRx Are Soaring WednesdayApril 5, 2023 | investorplace.comInflaRx (IFRX) Stock Pops as FDA Grants Emergency Use AuthorizationSee More Headlines IFRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IFRX Company Calendar Last Earnings5/11/2023Today6/06/2023Next Earnings (Estimated)8/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IFRX CUSIPN/A CIK1708688 Webwww.inflarx.de Phone493641508180FaxN/AEmployees55Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.00 High Stock Price Forecast$25.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+237.3%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.56% Return on Assets-25.39% Debt Debt-to-Equity RatioN/A Current Ratio11.24 Quick Ratio11.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.08 per share Price / Book2.00Miscellaneous Outstanding Shares44,700,000Free Float37,417,000Market Cap$185.51 million OptionableNot Optionable Beta0.97 Key ExecutivesNiels Christoph RiedemannChief Executive Officer & Executive DirectorThomas TaapkenChief Financial OfficerRenfeng GuoExecutive Director & Chief Scientific OfficerMaria HabelVP, Head-Pre-Clinical Research & DevelopmentBruce P. BurnettVice President & Head-Medical AffairsKey CompetitorsCara TherapeuticsNASDAQ:CARAAadi BioscienceNASDAQ:AADIMerrimack PharmaceuticalsNASDAQ:MACKFulcrum TherapeuticsNASDAQ:FULCAkebia TherapeuticsNASDAQ:AKBAView All CompetitorsInstitutional OwnershipJPMorgan Chase & Co.Bought 61,963 shares on 5/18/2023Ownership: 0.160%Susquehanna International Group LLPBought 78,575 shares on 5/16/2023Ownership: 0.240%Commonwealth Equity Services LLCSold 2,500 shares on 5/11/2023Ownership: 0.201%Raymond James Financial Services Advisors Inc.Bought 21,930 shares on 4/14/2023Ownership: 0.349%Raymond James & AssociatesBought 14,942 shares on 4/14/2023Ownership: 0.127%View All Institutional Transactions IFRX Stock - Frequently Asked Questions Should I buy or sell InflaRx stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IFRX shares. View IFRX analyst ratings or view top-rated stocks. What is InflaRx's stock price forecast for 2023? 5 equities research analysts have issued 12-month price targets for InflaRx's shares. Their IFRX share price forecasts range from $8.00 to $25.00. On average, they expect the company's share price to reach $14.00 in the next year. This suggests a possible upside of 237.3% from the stock's current price. View analysts price targets for IFRX or view top-rated stocks among Wall Street analysts. How have IFRX shares performed in 2023? InflaRx's stock was trading at $3.10 at the beginning of the year. Since then, IFRX stock has increased by 33.9% and is now trading at $4.15. View the best growth stocks for 2023 here. Are investors shorting InflaRx? InflaRx saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 705,400 shares, a decline of 26.3% from the April 30th total of 956,900 shares. Based on an average daily volume of 2,410,000 shares, the short-interest ratio is presently 0.3 days. View InflaRx's Short Interest. When is InflaRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023. View our IFRX earnings forecast. How were InflaRx's earnings last quarter? InflaRx (NASDAQ:IFRX) issued its quarterly earnings data on Thursday, May, 11th. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03. What ETF holds InflaRx's stock ? Invesco Raymond James SB-1 Equity ETF holds 63,995 shares of IFRX stock, representing 0.23% of its portfolio. What other stocks do shareholders of InflaRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), Kadmon (KDMN) and Moderna (MRNA). When did InflaRx IPO? (IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. What is InflaRx's stock symbol? InflaRx trades on the NASDAQ under the ticker symbol "IFRX." Who are InflaRx's major shareholders? InflaRx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Raymond James Financial Services Advisors Inc. (0.35%), Susquehanna International Group LLP (0.24%), Commonwealth Equity Services LLC (0.20%), JPMorgan Chase & Co. (0.16%) and Raymond James & Associates (0.13%). How do I buy shares of InflaRx? Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is InflaRx's stock price today? One share of IFRX stock can currently be purchased for approximately $4.15. How much money does InflaRx make? InflaRx (NASDAQ:IFRX) has a market capitalization of $185.51 million. The company earns $-31,070,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. How can I contact InflaRx? InflaRx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The official website for the company is www.inflarx.de. The company can be reached via phone at 493641508180 or via email at jordan.zwick@inflarx.de. This page (NASDAQ:IFRX) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.